Rolf Kaiser - Infectious Diseases

Author Information

Rolf Kaiser is a distinguished researcher affiliated with the Institute of Virology at the University of Cologne in Germany. His expertise lies primarily in the field of infectious diseases, with a particular focus on virology. Rolf Kaiser has contributed significantly to the understanding of viral infections, their treatment, and resistance dynamics. His research has been crucial in shaping the current landscape of infectious disease management, particularly concerning HIV and other viruses.

Research Contributions

Throughout his career, Rolf Kaiser has authored numerous research papers that delve into various aspects of viral infections and their treatments. His recent works have explored the effectiveness of integrase strand transfer inhibitors in HIV-infected individuals across Europe, the detection of HLA-associated mutations using Bayesian models, and trends in drug resistance from 1981 to 2019. He has also contributed to understanding the interactions and dynamics of respiratory viruses, the characterization of HIV drug resistance, and the development of sensitive serological assays for SARS-CoV-2. His research is instrumental in addressing the challenges posed by drug resistance and optimizing treatment strategies for viral infections.

Aliases

Throughout his career, Rolf Kaiser has published under various aliases, including "R Kaiser" and "R. Kaiser." These aliases are commonly used in academic publications and databases, reflecting variations in name representation across different platforms.

Publication and Citation Metrics

Total Papers	403
Total Citations	10,786
h-index	54

Publications:

Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe.

DOI: 10.1111/hiv.13262

Year: 2022

HAMdetector: A Bayesian regression model that integrates information to detect HLA-associated mutations.

DOI: 10.1093/bioinformatics/btac134

Year: 2022

Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters

DOI: 10.3389/fmicb.2022.846943

Year: 2022

Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization

DOI: 10.1016/j.immuni.2021.12.003

Year: 2022

Characterization of HIV‐1 drug resistance among patients with failure of second‐line combined antiretroviral therapy in central Ethiopia

DOI: 10.1111/hiv.13176

Year: 2021

Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting

DOI: 10.1007/s10096-021-04169-7

Year: 2021

Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial

DOI: 10.1016/j.eclinm.2021.101082

Year: 2021

Adapting the geno2pheno[coreceptor] tool to HIV-1 subtype CRF01_AE by phenotypic validation using clinical isolates from South-East Asia.

DOI: 10.1016/j.jcv.2021.104755

Year: 2021

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

DOI: 10.1093/jac/dkab078

Year: 2021

Respiratory Viruses Dynamics and Interactions: Ten Years of Surveillance in Central Europe

DOI: 10.21203/rs.3.rs-957569/v1

Year: 2021

What is the FDA's Role in Public Health Campaigns?

What Are the Symptoms of Diseases Transmitted by Culex?

What Are the Potential Complications?

What is the Scope of Infectious Diseases?

How is Botulism Transmitted?

What are the Challenges in Managing Ebola?

How Does Climate Change Influence Infectious Diseases?

What is the Immune System?

Are There Different Types of Salmonella?

What Causes Headaches in Infectious Diseases?

Partnered Content Networks

Relevant Topics